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Regulation of epidermal growth factor receptor traffic by the
small GTPase RhoB
Alexandra Gampel*, Peter J. Parker† and Harry Mellor*
Members of the Rho family of small GTPases control
cell adhesion and motility through dynamic regulation
of the actin cytoskeleton. Although twelve family
members have been identified, only three of these —
RhoA, Rac and Cdc42 — have been studied in detail.
RhoA regulates the formation of focal adhesions and
the bundling of actin filaments into stress fibres. It is
also involved in other cell signalling pathways including
the regulation of gene expression and the generation of
lipid second messengers [1,2]. RhoA is very closely
related to two other small GTPases about which much
less is known: RhoB and RhoC (which are
approximately 83% identical). Perhaps the most
intriguing of these is RhoB. RhoA is largely cytosolic
but translocates to the plasma membrane on activation.
RhoB, however, is entirely localised to the cytosolic
face of endocytic vesicles [3,4]. This suggests a
potential role for RhoB in regulating endocytic traffic;
however, no evidence has been presented to support
this. RhoA has been shown to act at the plasma
membrane to regulate the clathrin-mediated
internalisation of transferrin receptor [5] and of the
muscarinic acetylcholine receptor [6]. We have recently
demonstrated that RhoB binds the RhoA effector, PRK1
and targets it to the endosomal compartment [7]. We
show here that RhoB acts through PRK1 to regulate the
kinetics of epidermal growth factor receptor traffic.
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Results and discussion
Internalised receptors undergo a variety of fates. Some,
such as the transferrin receptor, are recycled to the plasma
membrane whereas others, such as the epidermal growth
factor (EGF) receptor, are targeted to the lysosomal com-
partment for degradation (reviewed in [8]). These traffick-
ing decisions are made in an early sorting compartment,
which is reached by internalised receptors within
5 minutes [9]. Final commitment of the EGF receptor to
degradation in the lysosome occurs in a prelysosomal com-
partment called the multivesicular body (MVB). Here the
receptor is sorted into internal membranes by a process
that involves receptor kinase activity [10]. The MVBs
then fuse with the lysosomal membrane, delivering EGF
receptor for degradation [11]. As RhoB has been shown to
be associated with both early endosomal vesicles and
MVBs [3,4], we have used a single cell assay to examine
the potential involvement of RhoB in EGF receptor
traffic. Before EGF treatment, the EGF receptor is
located mainly in the plasma membrane (Figure 1a).
Within 5–10 minutes of stimulation the receptor is clus-
tered and internalised into small vesicles corresponding to
early endosomes (Figure 1d). The receptor reaches larger
perinuclear structures by 30 minutes, with some loss of
signal at 60 minutes as the receptor begins to reach the
lysosomal compartment (Figures 1g,j). By 120 minutes,
few EGF-receptor-positive structures remain, owing to
lysosomal degradation of the signal (data not shown).
Overexpression of RhoB had no effect on the distribution
of EGF receptor in cells not treated with EGF nor did it
affect internalisation of the activated receptor (Figure 1a,d).
RhoB had, however, a marked effect on the movement of
internalised receptor to the prelysosomal compartment
(Figure 1g). In cells overexpressing RhoB, the EGF recep-
tor was present at 30 minutes in a large number of small
vesicles that did not concentrate around the nucleus. In
this respect, its distribution resembled that at 10 minutes
in either overexpressing or untransfected cells (Figure 1m),
suggesting that receptor movement from early to late
endosomal compartments had been retarded. Overlay of
the EGF receptor and RhoB signals showed that this retar-
dation occurred as the receptor entered the RhoB-positive
compartment (Figure 2b). By 60 minutes the EGF recep-
tor had largely exited this compartment (Figure 2c) and
there was a less pronounced difference in distribution com-
pared with untransfected cells (Figure 1j,m). Similar
results were obtained with RhoB-Q63L, an activated form
of the GTPase (data not shown). RhoB-T19N, an inactive
form of the GTPase that is nevertheless targeted to endo-
somes in HeLa cells, was without effect on EGF receptor
traffic, demonstrating that RhoB activation is required for
this action (data not shown).
RhoA has been shown to regulate the internalisation of
the transferrin receptor at the plasma membrane [5].
Given that RhoA and RhoB are essentially identical in
their effector-binding regions, it seemed possible that the
differential localisation of the two GTPases might be the
key to their action; that is, that both RhoA and RhoB
might regulate endocytosis through the same effectors,
with RhoA acting at the plasma membrane and RhoB in a
later endosomal compartment. RhoA had no effect on the
distribution of receptor 30 minutes after EGF treatment
(Figure 3c). RhoA also had no effect on EGF receptor
internalisation (Figure 3a), however, or indeed on any
stage of EGF receptor traffic (data not shown). Similar
results were seen with the constitutively activated RhoA-
Q63L mutant although, as reported previously [5], this
mutant totally blocked internalisation of the transferrin
receptor (data not shown). Taken together, these data
demonstrate that regulation of EGF receptor traffic is a
RhoB-specific effect.
In previous work we showed that RhoB binds to the PRK1
kinase (PKN) and targets it to the endosomal compart-
ment. Endosomal binding of PRK1 is accompanied by a
shift in mobility of the kinase on SDS–PAGE, suggesting
that translocation is coupled to activation [7]. Having iden-
tified an endosomal function for RhoB we investigated the
potential involvement of PRK1. RhoA proteins with point
mutations at residue F39 show differential binding to
downstream effectors; for example, RhoA-F39A does not
interact with kinases PRK1 or ROCK but still binds to the
mDia2 protein. Such RhoA mutants have been used to
discriminate between different downstream branches of
the RhoA signalling pathways [12]. Like RhoA, RhoB-
F39G was unable to bind PRK1 (Figure 4a) and overex-
pression of this mutant had no effect on EGF receptor
traffic (Figure 4b), consistent with a potential involvement
of PRK1 in this process. As some substitutions at F39 in
RhoA make it unable to bind to ROCK, we investigated
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Figure 1
RhoB regulates EGF receptor (EGFR) traffic. Cells were transfected
with RhoB and then treated for (a–c) 0, (d–f) 10, (g–i) 30 or
(j–l) 60 min with 100 ng/ml EGF. Cells were stained for endogenous
EGF receptor (green) and RhoB (red). Panels c,f,i and l show phase-
contrast images of the cells. Overexpression of RhoB caused slight
spreading of some cells and staining with phalloidin revealed an
increase in actin stress fibres, similar to that seen with RhoA (data not
shown). The scale bar represents 10 µm. (m) EGF-receptor-positive
vesicles fell into three morphological classes: small 250 nm vesicles
seen at early time points, intermediate sized 250 nm–500 nm vesicles
seen mainly between 10 and 30 min of EGF treatment, and larger,
> 500 nm, heterologous structures, seen at later time points. A series
of randomised confocal images were taken of control cells and cells
overexpressing RhoB at the various treatment times and imported into
Adobe Photoshop. The distribution of EGF receptor between the three
classes of vesicles was determined. Each data point represents
30 cells (10 cells, three experiments).
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Figure 2
RhoB regulates transit of EGF receptor through the RhoB-positive
compartment. The figure shows overlays of sections (quadrants) of
cells stained for endogenous EGF receptor (green) and RhoB (red)
after EGF treatment for (a) 10, (b) 30 or (c) 60 min. Significant
co-localisation (yellow) of RhoB and EGF receptor is seen after 30 min
of stimulation. The scale bar represents 1 µm.
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whether this Rho effector was involved in the regulation
of EGF receptor traffic by RhoB. Treatment of cells with
the specific ROCK inhibitor Y-27632 did not block the
effects of RhoB on EGF receptor traffic, and overexpres-
sion of ROCK or an activated ROCK mutant did not
mimic the regulation of traffic by RhoB (data not shown). 
Finally, we directly examined the role of PRK1 in RhoB
signalling by coexpressing RhoB with either wild-type
PRK1 or the inactive mutant PRK1-K644M. We have pre-
viously found that this approach requires careful interpre-
tation of the results as overexpression of either wild-type or
inactive PRK1 can cause inhibition of Rho signalling path-
ways that do not involve PRK1, such as actin stress fibre
formation. This is presumably due to a titration of Rho
GTPase by PRK1 away from the relevant downstream sig-
nalling protein (H.M. and P.J.P., unpublished results).
This nonspecific inhibitory effect was not observed here.
Coexpression of wild-type PRK1 with RhoB mildly poten-
tiated the effects of RhoB on EGF receptor traffic
(Figure 4c,i), whereas coexpression of RhoB with the
kinase-dead PRK1-K644M mutant completely blocked
these effects (Figures 4d,i). We conclude that RhoB signals
through PRK1 to regulate the kinetics of EGF receptor
traffic. This represents the first description of a function
for PRK1 in mammalian cells.
RhoA and RhoB are highly homologous at the protein level
and interact with an overlapping range of downstream effec-
tors. We have demonstrated here, however, a novel mecha-
nism of regulating EGF receptor traffic that is mediated
specifically by RhoB. Targeting of activated receptors to the
lysosome represents an ‘off-switch’ for mitogenic signals,
and the regulation of the kinetics of EGF receptor traffic by
RhoB thus has potential implications for EGF signalling.
Clearly, the most obvious hypothesis is that the gating of
EGF receptor traffic by RhoB might prolong the active life
of the receptor in the cell and therefore the duration of sig-
nalling. Other, more complicated, scenarios also need to be
considered. Many mitogenic receptors show compartment-
specific signalling; for example, when present at the plasma
membrane, the insulin receptor signals to phosphatidyli-
nositide 3-kinase, but it signals to the Ras-activated MAP
kinase pathway only when present on internalised endo-
somes [13]. It is therefore possible that RhoB functions to
alter the balance of signals from internalised receptors by
promoting signalling from internal compartments. In this
respect, it is interesting to note that the stimulation of HeLa
and other cell lines with EGF causes a dramatic increase in
RhoB (but not RhoA) expression that is detectable within
30 minutes and maximal after an hour [14]. This suggests a
potential involvement of RhoB in mediating both acute and
adaptive responses to EGF stimulation. We are currently
attempting to derive single-cell assays for EGF receptor sig-
nalling to address these questions.
Materials and methods
Receptor grade EGF purified from murine submaxillary glands was
from Calbiochem. The specific ROCK inhibitor Y-27632 was gener-
ously provided by Yoshitomi Pharmaceuticals Ltd (Saitama, Japan).
Rabbit polyclonal antibodies to RhoA and RhoB were from Santa Cruz.
The monoclonal anti-EGF receptor antibody EGFR1 and polyclonal
antibody to PRK1 were as previously described [15,16]. Cy2-conju-
gated and Cy3-conjugated secondary antibodies were from Jackson
Laboratories. Constructs encoding the ROCK-1 kinase and the acti-
vated ROCK∆3 mutant were generously provided by Erik Sahai (Insti-
tute of Cancer Research, London).
HeLa cells were maintained in DMEM supplemented with 10% fetal
bovine serum (FBS). For immunofluorescence microscopy, cells were
plated on acid-washed coverslips and allowed to adhere overnight. The
following day, cells were transfected with various mammalian expression
vector constructs (in pcDNA3; Invitrogen) using Transfast lipid
(Promega). After exposure to the lipid–DNA mix for 7 h, the cells were
washed into serum-free DMEM supplemented with 0.1% fatty-acid-free
BSA and left for a further 14 h before experimentation. EGF treatment
was carried out in the same medium supplemented with 100 ng/ml EGF.
Immunofluorescent staining was carried out essentially as described in
[7]. Cells were viewed using a Leica DM RBE confocal microscope
equipped with a Plan APO ×63/1.36 oil immersion lens. Cy2 and Cy3
were excited using the 488 nm and 568 nm lines of a Kr–Ar laser,
respectively. Series of images were taken at 0.5 µm intervals through the
Z-plane of the sample and were processed to form a projected image.
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Figure 3
RhoA does not control EGF receptor traffic. Cells were transfected
with RhoA and then treated for (a,b) 10 min or (c,d) 30 min with
100 ng/ml EGF. Cells were stained for endogenous EGF receptor
(green) and RhoA (red). RhoA expressed at this level caused a marked
increase in actin stress fibre formation as judged by phalloidin staining
(data not shown); however, no effect of RhoA on EGF receptor traffic
was observed. The RhoA polyclonal antibody is sensitive enough to
detect endogenous protein, resulting in some staining of untransfected
cells. The scale bar represents 10 µm.
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RhoB signals through PRK1 to regulate endocytic traffic. (a,e) Cells
were cotransfected with RhoB-F39G (red) and PRK1 (green): this
mutant form of RhoB is unable to translocate PRK1 to the endosomal
compartment. (b,f) Cells were transfected with RhoB-F39G and then
treated for 30 min with EGF. Expression of the RhoB-F39G mutant
(red) appeared to alter the morphology of the RhoB-positive
compartment but was without effect on the traffic of internalised
endogenous EGF receptor (green). Finally, cells were transfected with
RhoB and either (c,g) wild-type PRK1 or (d,h) kinase-dead PRK1
(PRK-KM) and then treated with EGF for 30 min. Cells were stained for
PRK1 (red) and endogenous EGF receptor (green). Overexpression of
wild-type PRK1 slightly potentiated the effects of RhoB on receptor
traffic (c,g), whereas overexpression of kinase-dead PRK1 blocked
those effects (d,h). Overexpression of kinase-dead PRK1 alone did not
have a significant effect on EGF receptor traffic (data not shown)
suggesting that RhoB action is acutely regulated, rather than being a
constitutively active process. The scale bar represents 10 µm. (i) The
intracellular distribution of endogenous EGF receptor was determined
for control cells or cells coexpressing RhoB and PRK1 or RhoB and
PRK1-K644M (PRK-KM), as described in the legend to Figure 1. Each
data point represents 30 cells (10 cells, three experiments).
